Clinical Trials Logo

Clinical Trial Summary

Oxytocin (OXT) is currently regarded as a crucial neuropeptide in the mediation of various human social behaviors, e.g. social affiliation, social recognition, and the modulation of anxiety, mood, and aggression. An impairment of social behavior, emotional regulation as well as increased stress reactions are characteristic of several psychiatric conditions, including schizophrenia, social anxiety and PTSD, in which there is also some evidence for OXT dysfunction. The startle reflex is a basic defensive reaction that can be modulated by emotional stimuli. The investigation of the startle reflex and of its modulation is a well-validated method to test stress reactions and emotional regulation. These processes are impaired in the same psychiatric diseases, in which OXT dysfunction was evidenced. Although previous animal studies showed that the dysfunction of brain OXT systems might be implicated in startle reflex and in its modulation, no study has been performed yet in human that investigated the influence of OXT administration on the startle response and on its affective modulation. A first aim of this study is to investigate the influence of OXT on stress reactivity and emotional modulation in healthy humans. A second aim is to develop a method for the investigation of anxiety disorders. Fifty male healthy participants will be tested using a randomized double-blind placebo-controlled cross-over design in two occasions; once with administration of 24 IU OXT, and once with placebo using nasal sprays while performing a computer-based experiment, in which emotional pictures and auditory startle probes are presented. We will measure the subject's subjective ratings of the pictures as well as the facial EMG activation, heart rate and electrodermal activation throughout the study. This project offers a unique opportunity to study the relationship between the OXT system and basic motivational and emotional behaviors. The investigation of these mechanisms is in turn greatly worthwhile, not only for understanding of the neurochemical and physiological processes involved in emotional regulation, but also for the comprehension of the neuroendocrine and neurophysiological mechanismsunderlying anxiety disorders. In the long term, it could open the possibilities of OXT as a psychobiological therapeutics of psychiatric disorders.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01066299
Study type Interventional
Source University of Zurich
Contact Chantal Martin Soelch, PhD
Phone +41 80)44 255
Email chantal.martinsoelch@usz.ch
Status Recruiting
Phase N/A
Start date May 2010
Completion date December 2012

See also
  Status Clinical Trial Phase
Recruiting NCT00166764 - A Study on Evaluation of Mental Health Index of Patients With Psychiatric Disorders N/A
Recruiting NCT06062953 - Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia Phase 2/Phase 3
Recruiting NCT05548946 - A Dimensional Model for Personality Disorders in Later Life N/A
Completed NCT03313154 - Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related
Completed NCT00783783 - CYP2D6 Pharmacogenetics in Risperidone-Treated Children N/A
Completed NCT01989728 - Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence N/A
Completed NCT03125083 - Role of Inflammation in Psychiatric Disorders in Patients With Cutaneous Lupus N/A
Completed NCT02987426 - Can Brief-mindfulness Interventions Improve Psychiatric Symptoms? Phase 2/Phase 3
Recruiting NCT05784818 - Up To Me: Erasing the Stigma of Mental Illness on College Campuses N/A
Completed NCT01786733 - Behavioral Activation - From Inpatient to Outpatient Services N/A
Withdrawn NCT03907124 - Clinical Utility of Pharmacogenomics of Psychotropic Medications Phase 4
Withdrawn NCT03809897 - Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders Phase 4
Not yet recruiting NCT02857322 - Effectiveness Accompaniment Perioperative Patients With Psychiatric Illness on the Lives Perioperative N/A
Terminated NCT02665988 - Adjunctive Transcranial Direct Current Stimulation N/A
Completed NCT01289080 - Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects Phase 1
Completed NCT01823250 - Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial Phase 2
Active, not recruiting NCT00982943 - The Epidemiological Study on Psychiatric Disorders and Psychotropic Drugs N/A
Completed NCT00184340 - Secured Internet-mediated Psychotherapy With Psychiatry Patients N/A
Completed NCT00184327 - Changes Following Inpatient Child-oriented Family Treatment Phase 1
Recruiting NCT04381845 - Immunity and Infections in the Psychiatric Population N/A